WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...
Oral presentation of data from RALLY-MF phase 2 trial of DISC-0974 in patients with myelofibrosis and anemia Additional abstracts highlighting updates on HELIOS open label extension study of ...
WATERTOWN, Mass., Dec. 13, 2022 /PRNewswire/ -- Disc Medicine, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results